Mineralys Therapeutics is a single-asset cardiorenal company that spent the second quarter buying the remaining economics of lorundrostat just as a larger rival occupied the drug class. The Food and Drug Administration accepted the new drug application in March and set a December action date. That sequence converts the equity from a clinical-option story into a launch-and-share story. AstraZeneca already received approval in May for baxdrostat, marketed as Baxfendy, the first aldosterone synthase inhibitor cleared for uncontrolled hypertension. Mineralys paid $200 million to extinguish running royalties owed to Tanabe Pharma. The company is no longer racing to invent a category. It is racing to enter one that a global franchise already opened.
The June recapitalization is the quarter's real operating event, not the headline loss. Management paired the Tanabe buyout with a follow-on that raised $150 million and a senior loan from Pharmakon Advisors. Only the first $100 million of that facility is funded. Later draws hinge on approval and sales. Cash still sits near $661 million after those moves, so the royalty check did not empty the treasury. What it did is convert a licensed economics stack into a higher-margin residual claim, while attaching a lender that gets paid if the launch works and can force amortization if approval slips. Shareholders now own more of every later prescription and more of the downside if the review fails.
Core research spending actually receded once the $200 million Tanabe charge is set aside, because the pivotal program ended last year. General and administrative expense rose to $25 million from $8 million a year earlier as commercial leadership arrived. That mix is what a pre-launch biotech is supposed to look like. The open question is whether a second aldosterone synthase inhibitor, arriving after Baxfendy, can take enough of the uncontrolled hypertension market to justify an enterprise value near $1.9 billion before the first script is written.